TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02408575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Notched filtering (verum)
Description: Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No filtering (placebo)
Description: Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering
Study: NCT02643901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: single SC injection
Study: NCT00251095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOCOSOL Paclitaxel
Description: 100 mg/m2/week
Study: NCT03048344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORH-2014
Description: ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORH-2014
Description: ORH-2014 capsule at recommended dose orally.
Study: NCT02643901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: single SC injection
Study: NCT01385410

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer mother support for continued exclusive breastfeeding
Description: Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer mother support for continued exclusive breastfeeding
Description: Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
Study: NCT00331630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: 30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT03801629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Morphine Dose
Description: Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Morphine Dose
Description: Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
Study: NCT04539821

Intervention type: OTHER
Group type: OTHER
Intervention: VCPM
Description: VCPM is a multi-component intervention consisting of already-established care processes and materials.
Study: NCT00320775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEGF Trap
Description: Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEGF Trap
Description: Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap.
Study: NCT01828580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active laparoscope positioner (AutoLap)
Study: NCT03859414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Dose 1
Description: CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
Study: NCT01452529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate q24h film-coated tablets
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match hydrocodone bitartrate q24h tablets
Description: Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
Study: NCT00004843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parathyroidectomy
Description: Standard parathyroidectomy with a bilateral approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Usual care
Study: NCT01375933

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NicVAX Vaccine
Description: NicVAX Vaccine given 6 times over 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NicVAX Vaccine
Description: NicVAX Vaccine given 6 times over 6 months
Study: NCT03859414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Dose 2
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supra-therapeutic Dose
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CHF 5993 placebo pMDI
Study: NCT02691182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Study: NCT04194203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
Study: NCT04502446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX130
Description: CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
Study: NCT04457830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: 3mg/kg every 3 weeks
Study: NCT04189445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle
Study: NCT01722760

Intervention type: PROCEDURE
Intervention: measurements
Study: NCT02123602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stabilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower extremity training only
Study: NCT03311282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infants bottles
Description: * angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~* extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* flexors at the base to enhance elasticity and flexibility of the teat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infants Bottles
Description: * large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~* flexors at the base to enhance elasticity and flexibility of the teat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infants Bottles
Description: * teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~* flexors at the base to enhance elasticity and flexibility of the teat
Study: NCT02416492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623 cells
Description: SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham Surgery
Study: NCT04452877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
Study: NCT01690130

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (Neuronetics)
Description: Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Neuronetics)
Description: Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Magnetic Stimulation
Description: The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
Study: NCT03213652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and/or biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT00663325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacid)
Description: Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
Study: NCT01505387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litramine
Description: Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
Study: NCT02324387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging (MBI)
Description: Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
Study: NCT02033525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-M-ALPHA and standard rehabilitation
Description: Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
Study: NCT02324387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m sestamibi
Description: 8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
Study: NCT00858533

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health at Work workplace health advice and support
Description: The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
Study: NCT02521142

Intervention type: OTHER
Intervention: Non-invasive OCT based optical angiography
Description: This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.

Intervention type: OTHER
Intervention: Non-invasive OCT based optical angiography
Description: This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.

Intervention type: OTHER
Intervention: Oxymap T1
Description: The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.

Intervention type: OTHER
Intervention: Oxymap T1
Description: The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
Study: NCT02033525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Standard rehabilitation program
Study: NCT03262298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD22-CAR-transduced T cells
Description: a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
Study: NCT03788265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: harvest and inject micro-fragment adipose tissue
Study: NCT03776903

Intervention type: OTHER
Intervention: ZIKV Detect™ 2.0 IgM Capture ELISA
Description: De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)

Intervention type: OTHER
Intervention: ZIKV Detect™ 2.0 IgM Capture ELISA
Description: De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
Study: NCT00252551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Study: NCT02521142

Intervention type: OTHER
Intervention: OCT
Description: non-invasive imaging of retinal and choroidal structures.

Intervention type: OTHER
Intervention: OCT
Description: non-invasive imaging of retinal and choroidal structures.

Intervention type: OTHER
Intervention: FLA/ICG angiography
Description: Fluorescein Angiography and Indocianine Angiography
Study: NCT00252551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple surgery
Description: Surgery without device
Study: NCT02347930

Intervention type: OTHER
Intervention: kidney ultrasound
Description: kidney ultrasound
Study: NCT00783796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System
Description: Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
Study: NCT00704418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: sterile ophthalmic solution
Study: NCT02521142

Intervention type: OTHER
Intervention: FLA/ICG angiography
Description: Fluorescein Angiography and Indocianine Angiography
Study: NCT00620750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release injectable naltrexone (Vivitrol)
Description: Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
Study: NCT03823781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: The study intervention is an intravenous infusion of milrinone or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The study intervention is an intravenous infusion of milrinone or placebo.